Shane Schaffer, Chairman & CEO, and Peter J. Werth, Board Member of Cingulate, were recently guests on Benzinga's All Access.<br /><br />Cingulate is a biotechnology company that is developing drugs for a range of underserved conditions. The company has developed a proprietary technology called Precision Timed Release™ (PTR™). The technology allows a single pill to contain multiple doses of a drug, allowing for relief of the pill burden many people with chronic conditions suffer.<br /><br />The company is preparing an application for new drug approval for its lead candidate, CTx-1301.
